Kelly has not made a statement yet other than the 1 sentence in the Electrome PR, "We see continued momentum in the adoption of bioelectric therapies, and this initiative represents a step toward broader integration of these technologies across clinical and consumer settings." stated Kelly Whelan, CEO of BioElectronics Corp.
https://www.prnewswire.com/news-releases/elec...23090.html
The feeling is that she is waiting for Electrome to remit the full amount of the initial Electrome device order before she does a BIEL PR. This is not a merger, it looks like Electrome received the US rights for ActiPatch and RecoveryRx.
Some details have surfaced from the online meeting Mayer held regarding giving BIEL shareholders an opportunity to invest in Electrome's 'seed funding'. You should go to the other board to get a feel for that.
Take care of yourself.